Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Brachytherapy is Scopus-indexed (Q3, CiteScore 2.8), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Elsevier Inc..
Checked against the index lists dated .
ISSN 1538-4721Verify ISSN ↗1873-1449Verify ISSN ↗
Publisher: Elsevier Inc.
Cost to publish: About US$3,000 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Radiology, Nuclear Medicine and Imaging | 187 / 361 | 48th | Q3 |
| Oncology | 267 / 428 | 37th | Q3 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2002–present, best quartile Q3, CiteScore 2.8.
Brachytherapy is Q3 in Radiology, Nuclear Medicine and Imaging (rank 187 of 361) and Q3 in Oncology (rank 267 of 428), by CiteScore 2025.
Brachytherapy is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 2.8, which places it in quartile Q3 at the 48th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.572, quartile Q2, with an H-index of 62.
The publisher lists an article processing charge of about US$3,000 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Brachytherapy is published by Elsevier Inc. Its print ISSN is 1538-4721 and its online ISSN is 1873-1449.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Brachytherapy has an h-index of 66 and a 2-year mean of 0.54 citations per paper (OpenAlex). Its Scopus CiteScore is 2.8, quartile Q3. On 2-year citations it ranks #265 of 346 Scopus journals in Radiology, Nuclear Medicine and Imaging.
Brachytherapy published 264 papers in 2025; its busiest recent year was 2021 with 432. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 98 research articles (2025–2026), authors are most often from United States (41.2%), India (15.8%) and Canada (8.5%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.